Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR
Int J Tuberc Lung Dis. 2013 17 (12): 1531-7

PMID: 24200264 · PMCID: PMC5451112 · DOI:10.5588/ijtld.13.0423

SETTING - A large randomized controlled trial recently showed that for treating latent tuberculous infection (LTBI) in persons at high risk of progression to tuberculosis (TB) disease, a 12-dose regimen of weekly rifapentine plus isoniazid (3HP) administered as directly observed treatment (DOT) can be as effective as 9 months of daily self-administered isoniazid (9H).

OBJECTIVES - To assess the cost-effectiveness of 3HP compared to 9H.

DESIGN - A computational model was designed to simulate individuals with LTBI treated with 9H or 3HP. Costs and health outcomes were estimated to determine the incremental costs per active TB case prevented and per quality-adjusted life year (QALY) gained by 3HP compared to 9H.

RESULTS - Over a 20-year period, treatment of LTBI with 3HP rather than 9H resulted in 5.2 fewer cases of TB and 25 fewer lost QALYs per 1000 individuals treated. From the health system and societal perspectives, 3HP would cost respectively US$21,525 and $4294 more per TB case prevented, and respectively $4565 and $911 more per QALY gained.

CONCLUSIONS - 3HP may be a cost-effective alternative to 9H, particularly if the cost of rifapentine decreases, the effectiveness of 3HP can be maintained without DOT, and 3HP treatment is limited to those with a high risk of progression to TB disease.

MeSH Terms (17)

Antitubercular Agents Computer Simulation Cost-Benefit Analysis Directly Observed Therapy Drug Administration Schedule Drug Costs Drug Therapy, Combination Hospital Costs Humans Isoniazid Latent Tuberculosis Models, Economic Quality-Adjusted Life Years Rifampin Time Factors Treatment Outcome United States

Connections (1)

This publication is referenced by other Labnodes entities: